Pharmadrug Inc
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs fo… Read more
Pharmadrug Inc (LMLLF) - Total Assets
Latest total assets as of September 2025: $557.24K USD
Based on the latest financial reports, Pharmadrug Inc (LMLLF) holds total assets worth $557.24K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmadrug Inc - Total Assets Trend (2011–2024)
This chart illustrates how Pharmadrug Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmadrug Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharmadrug Inc's total assets of $557.24K consist of 20.7% current assets and 79.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.5% |
| Accounts Receivable | $23.01K | 3.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $564.70K | 79.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Pharmadrug Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmadrug Inc's current assets represent 20.7% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, up from 0.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 79.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 79.3% of total assets.
Pharmadrug Inc Competitors by Total Assets
Key competitors of Pharmadrug Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Pharmadrug Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharmadrug Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pharmadrug Inc is currently not profitable relative to its asset base.
Pharmadrug Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.10 | 7.57 |
| Quick Ratio | 0.01 | 0.10 | 7.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.04 Million | $ -1.87 Million | $ 4.07 Million |
Pharmadrug Inc - Advanced Valuation Insights
This section examines the relationship between Pharmadrug Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 1.40 |
| Asset Growth Rate (YoY) | -40.6% |
| Total Assets | $711.80K |
| Market Capitalization | $996.23K USD |
Valuation Analysis
Above Book Valuation: The market values Pharmadrug Inc's assets above their book value (1.40 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Pharmadrug Inc's assets decreased by 40.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharmadrug Inc (2011–2024)
The table below shows the annual total assets of Pharmadrug Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $711.80K | -40.64% |
| 2023-12-31 | $1.20 Million | -90.10% |
| 2022-12-31 | $12.11 Million | -37.95% |
| 2021-12-31 | $19.52 Million | +42.60% |
| 2020-12-31 | $13.69 Million | +31.89% |
| 2019-12-31 | $10.38 Million | +876.97% |
| 2018-12-31 | $1.06 Million | +961.16% |
| 2017-12-31 | $100.11K | -12.60% |
| 2016-12-31 | $114.55K | -98.54% |
| 2015-12-31 | $7.87 Million | -5.03% |
| 2014-12-31 | $8.28 Million | +984.57% |
| 2013-12-31 | $763.74K | -34.98% |
| 2012-12-31 | $1.17 Million | +291.52% |
| 2011-12-31 | $300.00K | -- |